<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02035046</url>
  </required_header>
  <id_info>
    <org_study_id>P120111</org_study_id>
    <nct_id>NCT02035046</nct_id>
  </id_info>
  <brief_title>Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter</brief_title>
  <acronym>HEPHYGI</acronym>
  <official_title>Clinical Significance of Heterozygosity for Mutations of the SLC12A3 Gene Coding for the Thiazide Sensitive Na-Cl Cotransporter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gitelman syndrome is a salt wasting tubulopathy caused by mutations in the SLC12A3 gene
      coding for the thiazide sensitive sodium chloride cotransporter. This disease mimics the
      chronic treatment with thiazide diuretics and is characterized by renal hypokalemia, low to
      normal blood pressure, hypocalciuria and hypomagnesemia. The purpose of this study is to
      determine whether the heterozygous carriers present the metabolic risks and/or the benefits
      of this disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Gitelman syndrome (GS), is an autosomal recessive salt wasting tubulopathy caused mainly by
      loss of function mutations in the SLC12A3 gene coding for the thiazide sensitive
      sodium-chloride cotransporter (NCC). Thus, GS mimics a chronic treatment with high doses of
      thiazide diuretics. NCC is expressed in the distal convoluted tubule, which is responsible
      for 7% of NaCl reabsorption. GS is the more frequent hereditary tubulopathie with estimated
      prevalence of 1/40000, which implicates that 1% of general population are heterozygous
      carriers (600 000 in France). Previous publications suggest that the apparently asymptomatic
      heterozygous carriers could present some clinical traits of GS or chronic thiazide treatment.
      These including: beneficial aspects (low blood pressure, low urinary calcium excretions) or
      metabolic risks (hypokalemia, insulin resistance). Nevertheless, these studies do not
      evaluate all the aspects and blood pressure was evaluated once in hospital setting. This
      study aims to compare home monitoring blood pressure; salt balance; potassium, glucose lipid
      and mineral metabolism and vascular function in 80 heterozygous carriers, 80 GS patients and
      80 controls persons (without mutations in SLC12A3 gene).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic blood pressure evaluated by self-measurement</measure>
    <time_frame>3 days</time_frame>
    <description>self-measurement at home, 3 times a day during 3 consecutive days</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Salt balance</measure>
    <time_frame>1 day</time_frame>
    <description>Blood renin and aldosterone measurements, 24h urinary sodium and aldosterone excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Potassium metabolism</measure>
    <time_frame>1 day</time_frame>
    <description>Dietary intake, blood potassium and 24 h urinary potassium excretion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose and lipide metabolism</measure>
    <time_frame>1 day</time_frame>
    <description>BMI, blood glucose, insulin, cholesterol, LDL, HDL and triglycerides.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oral glucose tolerance test</measure>
    <time_frame>1 day</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mineral metabolism</measure>
    <time_frame>1 day</time_frame>
    <description>Blood and urinary calcium, magnesium and phosphate. bone remodeling markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal fonction</measure>
    <time_frame>1 day</time_frame>
    <description>Estimated GFR, proteinuria and albuminuria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular fonction evaluation</measure>
    <time_frame>1 day</time_frame>
    <description>Pulse wave analysis and central blood pressure. Blood and urinary vascular fonction markers</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Heterozygous Carriers of Gitelman Syndrome</condition>
  <arm_group>
    <arm_group_label>study's population</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Samplings of blood</intervention_name>
    <arm_group_label>study's population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sampling of urine</intervention_name>
    <arm_group_label>study's population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Measure of the blood pressure</intervention_name>
    <arm_group_label>study's population</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>glycemia test</intervention_name>
    <arm_group_label>study's population</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Gitelman syndrome patients, relatives carrying heterozygous mutations and relatives or
        healthy voluntarees without mutations.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rosa Vargas-Poussou, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Departement of Genetics. Assistance Publique Hôpitaux de Paris,Hôpital Européen Georges Pompidou.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Anne Blanchard, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Clinical Research Center. Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou. Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie Essig, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Departement of Nephrology. Centre Hospitalier Universitaire. Limoges, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jean Philippe Haymann, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Functional Investigations. Assistance Publique Hôpitaux de Paris, Hôpital Tenon, Paris, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ivan Tack, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Functional Investigations. Centre Hospitalier Universitaire, Hôpital de Rangueil. Toulouse, France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laurence DUBOURG, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Functional Investigations. Hospices Civils de Lyon, Hôpital Edouard Herriot. Lyon, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nephrology Department. Centre Hospitalier Universitaire, Hôpital Dupuytren</name>
      <address>
        <city>Limoges</city>
        <zip>87042 Limoges cedex</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Functional Investigations. Hospices Civils de Lyon, Hôpital Edouard Herriot.</name>
      <address>
        <city>Lyon</city>
        <zip>69437 Lyon</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Functional Investigations. Assistance Publique Hôpitaux de Paris, Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Center. Assistance Publique Hôpitaux de Paris, Hôpital Européen Georges Pompidou.</name>
      <address>
        <city>Paris</city>
        <zip>75908</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of Functional Investigations. Centre Hospitalier Universitaire, Hôpital de Rangueil.</name>
      <address>
        <city>Toulouse</city>
        <zip>31059 TOULOUSE cedex 9</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Tago N, Kokubo Y, Inamoto N, Naraba H, Tomoike H, Iwai N. A high prevalence of Gitelman's syndrome mutations in Japanese. Hypertens Res. 2004 May;27(5):327-31.</citation>
    <PMID>15198479</PMID>
  </reference>
  <reference>
    <citation>Fava C, Montagnana M, Rosberg L, Burri P, Almgren P, Jönsson A, Wanby P, Lippi G, Minuz P, Hulthèn LU, Aurell M, Melander O. Subjects heterozygous for genetic loss of function of the thiazide-sensitive cotransporter have reduced blood pressure. Hum Mol Genet. 2008 Feb 1;17(3):413-8. Epub 2007 Nov 1.</citation>
    <PMID>17981812</PMID>
  </reference>
  <reference>
    <citation>Ji W, Foo JN, O'Roak BJ, Zhao H, Larson MG, Simon DB, Newton-Cheh C, State MW, Levy D, Lifton RP. Rare independent mutations in renal salt handling genes contribute to blood pressure variation. Nat Genet. 2008 May;40(5):592-599. doi: 10.1038/ng.118. Epub 2008 Apr 6.</citation>
    <PMID>18391953</PMID>
  </reference>
  <reference>
    <citation>Hsu YJ, Yang SS, Chu NF, Sytwu HK, Cheng CJ, Lin SH. Heterozygous mutations of the sodium chloride cotransporter in Chinese children: prevalence and association with blood pressure. Nephrol Dial Transplant. 2009 Apr;24(4):1170-5. doi: 10.1093/ndt/gfn619. Epub 2008 Nov 25.</citation>
    <PMID>19033254</PMID>
  </reference>
  <reference>
    <citation>Ren H, Qin L, Wang W, Ma J, Zhang W, Shen PY, Shi H, Li X, Chen N. Abnormal glucose metabolism and insulin sensitivity in Chinese patients with Gitelman syndrome. Am J Nephrol. 2013;37(2):152-7. doi: 10.1159/000346708. Epub 2013 Jan 31.</citation>
    <PMID>23392128</PMID>
  </reference>
  <reference>
    <citation>Cruz DN, Simon DB, Nelson-Williams C, Farhi A, Finberg K, Burleson L, Gill JR, Lifton RP. Mutations in the Na-Cl cotransporter reduce blood pressure in humans. Hypertension. 2001 Jun;37(6):1458-64.</citation>
    <PMID>11408395</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 18, 2013</study_first_submitted>
  <study_first_submitted_qc>January 10, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2014</study_first_posted>
  <last_update_submitted>January 13, 2017</last_update_submitted>
  <last_update_submitted_qc>January 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gitelman</keyword>
  <keyword>Heterozygous SLC12A3 mutation</keyword>
  <keyword>Blood pressure</keyword>
  <keyword>Hypokalemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gitelman Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

